Michael Paglia, senior director of technical operations at Bluebird Bio, told attendees at Cell Therapy Bioprocessing & Commercialization that companies need to “better understand the evolution of the process”.
Paglia told a packed session on viral production that there is a “significant need to determine how to improve their internal process development”.
He reviewed a specific case focusing on the downstream process development of a lentiviral vector and how one company offset product loss in their downstream process.
Companies must also have “proven tech-transfer in order to ensure proper reproducibility whether the process is internal or outsourced”, he said.
Join the conversation on Twitter by following #IBC_CTB15
|
Share this article with your social network, just click below to share now!
|
|
|
